-$1.24 Earnings Per Share Expected for Flexion Therapeutics Inc (FLXN) This Quarter

Brokerages predict that Flexion Therapeutics Inc (NASDAQ:FLXN) will post earnings of ($1.24) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Flexion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.27) and the highest estimate coming in at ($1.20). Flexion Therapeutics posted earnings of ($0.75) per share during the same quarter last year, which suggests a negative year over year growth rate of 65.3%. The firm is scheduled to announce its next quarterly earnings report on Thursday, May 3rd.

According to Zacks, analysts expect that Flexion Therapeutics will report full-year earnings of ($4.89) per share for the current financial year, with EPS estimates ranging from ($5.63) to ($4.22). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.54) per share, with EPS estimates ranging from ($3.38) to ($0.28). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Flexion Therapeutics.

How to Become a New Pot Stock Millionaire

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.11) by ($0.27). The business had revenue of $0.36 million during the quarter, compared to analyst estimates of $1.29 million.

A number of equities analysts have recently weighed in on FLXN shares. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. BidaskClub lowered Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 20th. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th. Berenberg Bank started coverage on Flexion Therapeutics in a research note on Thursday, February 1st. They issued a “buy” rating and a $42.00 price objective for the company. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price objective (down previously from $37.00) on shares of Flexion Therapeutics in a research note on Friday, March 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. Flexion Therapeutics has a consensus rating of “Buy” and a consensus price target of $99.00.

Several large investors have recently bought and sold shares of FLXN. Advisory Services Network LLC purchased a new stake in Flexion Therapeutics during the fourth quarter valued at approximately $108,000. SG Americas Securities LLC bought a new position in Flexion Therapeutics in the third quarter worth approximately $135,000. Teacher Retirement System of Texas bought a new position in Flexion Therapeutics in the fourth quarter worth approximately $245,000. Eaton Vance Management grew its stake in Flexion Therapeutics by 37.2% in the fourth quarter. Eaton Vance Management now owns 12,900 shares of the specialty pharmaceutical company’s stock worth $323,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Berson & Corrado Investment Advisors LLC bought a new position in Flexion Therapeutics in the fourth quarter worth approximately $324,000. Institutional investors own 94.46% of the company’s stock.

NASDAQ:FLXN opened at $22.41 on Friday. Flexion Therapeutics has a 52-week low of $16.51 and a 52-week high of $32.25. The company has a current ratio of 13.02, a quick ratio of 12.96 and a debt-to-equity ratio of 0.58.

ILLEGAL ACTIVITY NOTICE: “-$1.24 Earnings Per Share Expected for Flexion Therapeutics Inc (FLXN) This Quarter” was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.wkrb13.com/2018/04/02/1-24-earnings-per-share-expected-for-flexion-therapeutics-inc-flxn-this-quarter.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply